Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2024 08:05 ET | Source: Palisade Bio, Inc.

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...
March 27, 2024 08:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end – Formation of Clinical...
October 11, 2023 09:05 ET | Source: Palisade Bio, Inc.

Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference

Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq:...
August 11, 2023 08:05 ET | Source: Palisade Bio, Inc.

Palisade Bio Reports Second Quarter 2023 Financial Results

– Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline – Strong financial position with cash to fund...
July 05, 2023 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute...
June 14, 2023 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Live webcast fireside chat on Thursday, June 22nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies...
June 01, 2023 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Promotes J.D. Finley to Chief Executive Officer

Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic...
May 24, 2023 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts

Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose optimization study with 25% enrollment...
April 06, 2023 09:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148

Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
January 09, 2023 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Tuesday, January 17th at 3:00 PM ET Carlsbad, CA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company...